Crizanlizumab (formerly SelG1) for Sickle Cell Disease

featured image
Indications: Sickle cell anaemia
Therapeutic Areas: Haematology
Year: 2017

Crizanlizumab is a medicine under development for the preventative treatment of SCD painful crisis. Circulating platelets (type of cells in the blood that has a role in blood clotting and stopping of bleeding) in SCD patients express higher levels of P-selectin, a protein that drives the blockage of blood vessels. Crizanlizumab acts by blocking P-selectin and thus can prevent blockage in small blood vessels and maintain blood flow. Therefore, if licensed, crizanlizumab will offer a new treatment option for patients with sickle cell-related pain crises.